ClinConnect ClinConnect Logo
Search / Trial NCT02682667

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Launched by NATIONAL CANCER INSTITUTE (NCI) · Feb 11, 2016

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Apheresis Products Immunological Diverse Malignan Premalignant Protein Natural History

ClinConnect Summary

This clinical trial is focused on understanding different types of cancer, including multiple myeloma, lymphoma, and non-small cell lung cancer. Researchers aim to collect and study tissue and blood samples from adults who either have cancer or a condition that could lead to cancer. By doing this, they hope to learn more about why some cancers respond better to treatments than others, which could help develop more effective therapies in the future.

To participate in the trial, you need to be at least 18 years old and have a diagnosis of cancer or a related condition. If you join, you will have some medical tests, including physical exams, blood tests, and possibly scans to locate your tumor. You may also provide samples like tissue from your tumor or undergo a procedure called apheresis, where blood is drawn, processed, and returned back to you. Throughout the study, the research team will keep in touch with you to check on your health. This study is currently recruiting participants and is open to anyone who meets the eligibility criteria.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • 1. Diagnosis of cancer, a premalignant/neoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant/neoplastic condition
  • 2. Age \>=18 years of age
  • 3. ECOG performance status of 0-3.
  • 5. Ability and willingness of subject to provide informed consent
  • Additional inclusion criteria pertinent only for participants undergoing apheresis
  • 1. Hemoglobin \>= 8 mg/dL and platelet count \> 75 K/microL
  • 2. Weight \>= 48 kg
  • 3. Central line in place or adequate venous access
  • EXCLUSION CRITERIA:
  • 1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.
  • 2. Inability to provide informed consent
  • 3. Pregnant or breastfeeding women

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Bethesda, Maryland, United States

Bethesda, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Scott M Norberg, D.O.

Principal Investigator

National Cancer Institute (NCI)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials